These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 23410140)
1. Psychotropic medication use and clinical outcomes among children and adolescents receiving system of care services. Drilea SK; Jowers K; Lichtenstein C; Hale M; Blau G; Stromberg S J Child Adolesc Psychopharmacol; 2013 Feb; 23(1):36-43. PubMed ID: 23410140 [TBL] [Abstract][Full Text] [Related]
2. Investigating geographic variation in use of psychotropic medications among youth in child welfare. Leslie LK; Raghavan R; Hurley M; Zhang J; Landsverk J; Aarons G Child Abuse Negl; 2011 May; 35(5):333-42. PubMed ID: 21620160 [TBL] [Abstract][Full Text] [Related]
3. Psychotropic medication use in a national probability sample of children in the child welfare system. Raghavan R; Zima BT; Andersen RM; Leibowitz AA; Schuster MA; Landsverk J J Child Adolesc Psychopharmacol; 2005 Feb; 15(1):97-106. PubMed ID: 15741791 [TBL] [Abstract][Full Text] [Related]
4. Psychotropic medication use in children and adolescents in an inpatient setting. Pejovic-Milovancevic M; Miletic V; Popovic-Deusic S; Draganic-Gajic S; Lecic-Tosevski D; Marotic V Psychiatriki; 2011; 22(4):314-9. PubMed ID: 22271844 [TBL] [Abstract][Full Text] [Related]
5. Psychotropic medication utilization at a group-home residential facility for children and adolescents. Handwerk ML; Smith GL; Thompson RW; Spellman DF; Daly DL J Child Adolesc Psychopharmacol; 2008 Oct; 18(5):517-25. PubMed ID: 18928416 [TBL] [Abstract][Full Text] [Related]
6. Use of psychotropic medication in children and adolescents with autism spectrum disorders. Coury DL; Anagnostou E; Manning-Courtney P; Reynolds A; Cole L; McCoy R; Whitaker A; Perrin JM Pediatrics; 2012 Nov; 130 Suppl 2():S69-76. PubMed ID: 23118256 [TBL] [Abstract][Full Text] [Related]
7. Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder. Klassen AF; Miller A; Fine S Pediatrics; 2004 Nov; 114(5):e541-7. PubMed ID: 15520087 [TBL] [Abstract][Full Text] [Related]
8. Predictors of medication adherence in children receiving psychotropic medication. Dean AJ; Wragg J; Draper J; McDermott BM J Paediatr Child Health; 2011 Jun; 47(6):350-5. PubMed ID: 21309880 [TBL] [Abstract][Full Text] [Related]
9. Psychotropic medication in children and adolescents in Germany: prevalence, indications, and psychopathological patterns. Koelch M; Prestel A; Singer H; Keller F; Fegert JM; Schlack R; Hoelling H; Knopf H J Child Adolesc Psychopharmacol; 2009 Dec; 19(6):765-70. PubMed ID: 20035595 [TBL] [Abstract][Full Text] [Related]
10. Medication use in US youth with mental disorders. Merikangas KR; He JP; Rapoport J; Vitiello B; Olfson M JAMA Pediatr; 2013 Feb; 167(2):141-8. PubMed ID: 23403911 [TBL] [Abstract][Full Text] [Related]
11. National trends in the mental health care of children, adolescents, and adults by office-based physicians. Olfson M; Blanco C; Wang S; Laje G; Correll CU JAMA Psychiatry; 2014 Jan; 71(1):81-90. PubMed ID: 24285382 [TBL] [Abstract][Full Text] [Related]
12. Pain among children and adolescents: restrictions in daily living and triggering factors. Roth-Isigkeit A; Thyen U; Stöven H; Schwarzenberger J; Schmucker P Pediatrics; 2005 Feb; 115(2):e152-62. PubMed ID: 15687423 [TBL] [Abstract][Full Text] [Related]
13. Initiation and change of psychotropic medication regimens among adolescents in inpatient care. Warner LA; Fontanella CA; Pottick KJ J Child Adolesc Psychopharmacol; 2007 Oct; 17(5):701-12. PubMed ID: 17979589 [TBL] [Abstract][Full Text] [Related]
14. Symptom clusters in children and adolescents receiving cisplatin, doxorubicin, or ifosfamide. Hockenberry MJ; Hooke MC; Gregurich M; McCarthy K; Sambuco G; Krull K Oncol Nurs Forum; 2010 Jan; 37(1):E16-27. PubMed ID: 20044328 [TBL] [Abstract][Full Text] [Related]
15. Use of outpatient mental health services and psychotropic medications among HIV-infected patients in a multisite, multistate study. Himelhoch S; Josephs JS; Chander G; Korthuis PT; Gebo KA; Gen Hosp Psychiatry; 2009; 31(6):538-45. PubMed ID: 19892212 [TBL] [Abstract][Full Text] [Related]
16. Prevalence and characteristics of psychotropic drug use in institutionalized children and adolescents with mild intellectual disability. Scheifes A; de Jong D; Stolker JJ; Nijman HL; Egberts TC; Heerdink ER Res Dev Disabil; 2013 Oct; 34(10):3159-67. PubMed ID: 23886758 [TBL] [Abstract][Full Text] [Related]
17. Interstate variations in psychotropic medication use among a national sample of children in the child welfare system. Raghavan R; Lama G; Kohl P; Hamilton B Child Maltreat; 2010 May; 15(2):121-31. PubMed ID: 20410022 [TBL] [Abstract][Full Text] [Related]
18. Medication persistence in Turkish children and adolescents with attention-deficit/hyperactivity disorder. Ayaz M; Ayaz AB; Soylu N; Yüksel S J Child Adolesc Psychopharmacol; 2014 Oct; 24(8):442-7. PubMed ID: 25010598 [TBL] [Abstract][Full Text] [Related]
19. Psychotropic medication changes, polypharmacy, and the risk of early readmission in suicidal adolescent inpatients. Fontanella CA; Bridge JA; Campo JV Ann Pharmacother; 2009 Dec; 43(12):1939-47. PubMed ID: 19934394 [TBL] [Abstract][Full Text] [Related]
20. Pediatric Psychotropic Polypharmacy: An Evaluation of the Correlates and Prevalence Across Assessment Cycles in the National Health and Nutrition Examination Survey. Bilsky S; Blumenthal H; Ramadan B; Lewis S; Leen-Feldner EW J Child Adolesc Psychopharmacol; 2022 Oct; 32(8):416-425. PubMed ID: 36074100 [No Abstract] [Full Text] [Related] [Next] [New Search]